NCT00619580 is a clinical trial in Positive E Coli Infections, sponsored by University of Pittsburgh.

Who is sponsoring NCT00619580?

NCT00619580 is sponsored by University of Pittsburgh.

What condition does NCT00619580 study?

NCT00619580 studies Positive E Coli Infections.

Is NCT00619580 still recruiting?

NCT00619580 is currently withdrawn. Last updated 5 December 2014.

Last reviewed 2014-12-05 · How we verify

NCT00619580

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ampicillin-sulbactam Resistant E.Coli at UPMC

Withdrawn Last updated 5 December 2014

What this trial tests

trial in Positive E Coli Infections. Withdrawn.

Timeline

1 February 2008

Primary endpoint
1 November 2014

1 December 2014

Quick facts

Lead sponsor	University of Pittsburgh
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	1 February 2008
Primary completion	1 November 2014
Estimated completion	1 December 2014
Sites	1 location across United States

Conditions studied

Positive E Coli Infections — all drugs for Positive E Coli Infections →

Sponsor

University of Pittsburgh

Who can join

18 and older, any sex, with Positive E Coli Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The aims of this study are to: Determine the risk factors for multidrug resistance (ESBL production) in bloodstream isolates of Gram negative bacilli,
Time frame: 5 years

Sponsor's own description

The information collected will optimize the management of patients with gram negative bacteremia. Approximately 300 patients with Gram negative bacteremia are cared for each year at UPMC-P. Published medical literature suggests that mortality from this infection exceeds 20%. The aim of this research is to determine the risk factors for bacteriologic failure of antibiotic therapy, risk factors for antibiotic resistance in bloodstream isolates and risk factors for mortality from Gram negative bacteremia. Modifiable risk factors can then be tackled by a future interventional study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Pittsburgh trials

Trials by the same sponsor.

NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00619580 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
Last refreshed: 5 December 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00619580.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing